New Haven, CT, United States of America

Mark Fields

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Yale University. Active years: 2023-2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mark Fields: Innovator in Ocular Treatment

Introduction

Mark Fields is a notable inventor based in New Haven, CT (US). He has made significant contributions to the field of ocular health, particularly in the treatment of retinal degenerations. With a total of 2 patents, Fields has focused on developing innovative methods and compounds to address serious eye disorders.

Latest Patents

Fields' latest patents include groundbreaking work on compounds and methods for treating or preventing anterior segment ocular disorders and retinal degenerations. His inventions provide methods for treating conditions such as age-related macular degeneration (AMD). The methods involve administering a pharmaceutical composition that contains effective amounts of specific compounds designed to prevent cellular damage and promote cell viability.

Career Highlights

Mark Fields is affiliated with Yale University, where he continues to advance research in ocular treatments. His work has garnered attention for its potential to improve the quality of life for individuals suffering from debilitating eye conditions.

Collaborations

Fields has collaborated with esteemed colleagues, including Lucian Del Priore and Huey Cai, to further enhance the impact of his research and innovations in the field of ocular health.

Conclusion

Mark Fields stands out as an influential inventor dedicated to improving ocular health through innovative treatments. His contributions are paving the way for advancements in the management of retinal disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…